OncBioMune Receives Allowance for Patent Covering New Targeted Cancer Treatment

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application #13/017,173 that covers the its transferrin transport technology for developing new, targeted cancer treatments. The patent to be issued from this allowed application, titled “Taxane-and taxoid-protein compositions,” carries a patent term to at least 2031.
According to the company news release:

OncBioMune’s transferrin transport technology is an innovative approach to chemotherapy that we believe represents an improvement of current cancer treatments that have already been proven effective, but come with limitations due to toxicity towards healthy cells and inefficient delivery specific to the tumor, amongst other things. Similarly the drug Abraxane®, which is estimated to have generated nearly $1 billion in sales in 2015, utilizes paclitaxel bound to human albumin to treat cancer to increase the effectiveness of the paclitaxel.

Dr. Jonathan Head, Chief Executive Officer at OncBioMune commented:

This patent is a very important addition to our intellectual property portfolio, as we believe our targeted therapeutics under its umbrella can represent the next generation of taxane and taxoid-based cancer treatments. Although their ability to slow cell proliferation is well known, taxanes are particularly insoluble, providing a unique set of challenges to drug developers. With our paclitaxel-gallium-transferrin composition, we have overcome this challenge. Lab studies support the thesis that we can deliver cytotoxic agents targeted selectively to the cancer cell, resulting in robust activity to inhibit cellular proliferation without damaging normal cells.

Click to view the full press release.